CSF2 and stroke disorder: GM-CSF is a likewise attractive candidate for clinical development, because it is clinically in use for a number of years in hematological indications, is anti-apoptotic and neuroprotective in vivo, passes the intact blood-brain barrier [3], and also has a neurogenic potential, likely beneficial for long-term stroke recovery.